resources were derived from public sources. One and two-way sensitivity analyses were performed for key input variables. Budget impact analysis extrapolates results of the (CM), using prevalence data, to a health plan with 1 million covered lives. An alternate time-dependent model addresses the impact associated with the sequencing of diagnostic tests. Results: The CM model predicts a base-case savings of $280 per patient for the diagnostic pathway that includes the novel IBS diagnostic blood panel. Sensitivity analyses predict a range of cost savings of $120 -$439. Budget impact analysis predicts a base case savings of $1,080,232 to the plan or $0.09 on a per member per month basis for the diagnostic pathway with the novel IBS diagnostic blood panel. The time dependent model indicates that the potential cost savings associated with the novel IBS blood test are attenuated over time. ConClusions: Current literature suggests that extensive diagnostic testing to diagnose IBS is not necessary. This economic evaluation indicates that the inclusion of a novel IBS diagnostic blood panel in the diagnostic process has the potential for significant cost savings due to the avoidance of unnecessary testing. is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting beta agonist (LABA) in a novel dry powder inhaler (DPI). A five year economic model was developed from a healthcare payer perspective to assess the impact of potentially improved inhalation technique on unscheduled healthcare events and costs, when switching adult patients with persistent asthma and chronic obstructive pulmonary disease (COPD) from market-leading DPIs in Spain -Symbicort® Turbuhaler® and Seretide® Accuhaler® -to DuoResp® Spiromax®. Methods: The eligible patient population was estimated from current confirmed Spanish asthma and COPD diagnosis rates, with the proportion receiving FDCs based on market research data. Costs of unscheduled healthcare events were taken from publicly available Spanish sources. The frequency of poor inhalation technique with the market-leading DPIs, and the associated increased risk of unscheduled healthcare events, were taken from a large (n= 1,664) cross-sectional Italian study. The hypothetical reduction in poor inhalation technique with DuoResp® Spiromax® was an assumption based on the novel attributes of the Spiromax® inhaler. Results: The model estimated that 266,657 adult patients used Symbicort® Turbuhaler® and 296,905 Seretide® Accuhaler® -and were therefore eligible to receive DuoResp® Spiromax® -annually, with 115,996 (43.5%) and 102,432 (34.5%) exhibiting poor inhalation technique, respectively. The total cost of unscheduled healthcare events associated with poor inhalation technique was estimated to be € 11.54 million annually. Assuming a hypothetical uptake of DuoResp® Spiromax® increasing from 6% in year 1 to 18% in year 4 and 5, an estimated 51,633 unscheduled healthcare events were avoided due to the predicted improvement in inhalation technique with DuoResp® Spiromax® compared with other DPIs, resulting in cost savings totalling € 4.79 million over five years. ConClusions: Introducing DuoResp® Spiromax® may reduce the occurrence of unscheduled healthcare events compared with market-leading DPIs, potentially resulting in cost savings. treatment. ConClusions: Inclusion of a novel IBS diagnostic blood panel in the diagnostic pathway has the potential for significant cost savings due to the avoidance of unnecessary testing. objeCtives: UK guidelines for the diagnosis of IBS in patients who meet diagnostic criteria include FBC, ESR, C -reactive protein and testing for coeliac disease to exclude other diseases. Despite these recommendations, referral for procedures such as flexible sigmoidoscopy, colonoscopy and ultrasound scanning continue and in the majority of this patient group, are considered to be unnecessary, subsequently placing an increased cost burden to National Health Services (NHS). A novel IBS diagnostic blood panel has been developed which tests for the presence of two biomarkers associated with IBS-D. This analysis estimates the potential cost impact to the NHS by introducing this test into the diagnostic pathway of IBS. Methods: Budget impact was based on a cost-minimization model to compare the costs associated with two possible diagnostic pathways: (1) with a novel IBS diagnostic blood panel and (2) exclusionary pathway and applied to the UK population 18-65yrs old. Model structure was based on current literature/ guidance from IBS expert. Direct medical expenses include, labs, diagnostic procedures, visits in £ and weighted by utilization provided by a practicing gastroenterologist in the UK. Results: Gastroscopy, flexible sigmoidoscopy, and colonoscopy were the most common diagnostic (instrumental) procedures reported with estimated utilization rates of 55%, 55% and 35%, respectively. Corresponding charges were £200, £400 and £400, respectively. Net savings in the base case of £57 favored the IBS diagnostic blood panel pathway (assumes 75% of test positive patients receive IBS-D treatment) vs the exclusionary pathway. If clinicians use the test 50% of the time for the 30% of the estimated 446,382 people who might have IBS-D who seek treatment, net potential savings to NHS is £12,721,891. ConClusions: Inclusion of a novel IBS diagnostic blood panel in the diagnostic pathway has the potential for significant cost savings due to the avoidance of unnecessary testing. objeCtives: Current guidelines recommend a positive strategy based on symptom criteria without alarm features vs diagnostic exclusion which includes several laboratory and diagnostics procedures to exclude other organic conditions. A novel IBS diagnostic blood panel tests for the presence of two biomarkers associated with IBS-D which can complement the positive strategy. This analysis assesses the cost impact to the Danish healthcare system by introducing this test into the diagnostic pathway. Methods: A budget impact model was based on a cost-minimization decision model developed to compare the costs associated with two possible diagnostic pathways: (1) diagnostic pathway with a novel IBS diagnostic blood panel and (2) exclusionary diagnostic pathway and applied to the Danish population 18-65yrs old. Model structure was based on current literature and guidance from IBS expert clinicians. Direct medical expenses for laboratory tests, diagnostic procedures and visit costs were included in Danish Krone and weighted by utilization rates estimated by a practicing gastroenterologist in Denmark. Indirect cost only included time off work based on a published Danish study. Results: Sigmoidoscopy, colonoscopy and SBFT were the most common diagnostic procedures reported with estimated utilization rates of 35%, 35% and 15%, respectively. Corresponding charges were kr4819, kr4819 and kr1861, respectively. Estimated total base case charges for the IBS diagnostic blood panel pathway ( objeCtives: The diagnosis of diarrhea predominant irritable bowel syndrome (IBS-D) is based on clinical presentation and several laboratory and diagnostic procedures to exclude other organic conditions. A novel IBS diagnostic blood panel has been developed which tests for the presence of two biomarkers associated with IBS-D. This study assesses the cost implications associated with introducing this test into the diagnostic pathway. Methods: A cost-minimization (CM) decision tree model was constructed to compare the costs associated with two possible diagnostic pathways: (1) diagnostic pathway with novel IBS diagnostic blood panel and (2) exclusionary diagnostic pathway (i.e. standard of care). Model structure was based on current literature and guidance from IBS expert clinicians. Costs for
objeCtives: Irritable bowel syndrome presents a significant burden to patients and to the healthcare system in Mexico. An IBS diagnosis is based on Rome criteria; however, laboratory tests and diagnostic procedures are required to exclude organic conditions such as inflammatory bowel disease (IBD). A new IBS diagnostic blood panel has been developed which tests for the presence of two biomarkers associated with IBS-D. This analysis assesses the cost impact to the Mexican private practice. Methods: Budget impact analysis (BIA) was based on a cost-minimization (CM) decision model developed to compare the costs associated with two possible diagnostic pathways: (1) diagnostic pathway with a new IBS diagnostic blood panel and (2) exclusionary diagnostic pathway (i.e. standard of care) and applied to the Mexican population. Model structure was based on current literature and guidance from IBS expert clinicians. Direct medical expenses for laboratory tests, diagnostic procedures and visit costs were included in Mexican pesos and weighted by utilization rates provided by practicing gastroenterologists in private practice in Mexico. The indirect cost estimate was based on the literature and only included absenteeism, adjusted for per capita income. The base case assumes that 75% of patients who receive a positive test result will proceed to IBS-D treatment. For the BIA, it is assumed that 30% of IBS-D patients will seek care, and clinicians use the test for 50% of patients presenting with IBS-D symptoms. is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting beta agonist (LABA) in a novel dry powder inhaler (DPI). A five year economic model was developed from a healthcare payer perspective to assess the impact of potentially improved inhalation technique on unscheduled healthcare events and costs, when switching adult patients with persistent asthma and chronic obstructive pulmonary disease (COPD) from market-leading DPIs in Spain -Symbicort® Turbuhaler® and Seretide® Accuhaler® -to DuoResp® Spiromax®. Methods: The eligible patient population was estimated from current confirmed Spanish asthma and COPD diagnosis rates, with the proportion receiving FDCs based on market research data. Costs of unscheduled healthcare events were taken from publicly available Spanish sources. The frequency of poor inhalation technique with the market-leading DPIs, and the associated increased risk of unscheduled healthcare events, were taken from a large (n= 1,664) cross-sectional Italian study. The hypothetical reduction in poor inhalation technique with DuoResp® Spiromax® was an assumption based on the novel attributes of the Spiromax® inhaler. Results: The model estimated that 266,657 adult patients used Symbicort® Turbuhaler® and 296,905 Seretide® Accuhaler® -and were therefore eligible to receive DuoResp® Spiromax® -annually, with 115,996 (43.5%) and 102,432 (34.5%) exhibiting poor inhalation technique, respectively. The total cost of unscheduled healthcare events associated with poor inhalation technique was estimated to be € 11.54 million annually. Assuming a hypothetical uptake of DuoResp® Spiromax® increasing from 6% in year 1 to 18% in year 4 and 5, an estimated 51,633 unscheduled healthcare events were avoided due to the predicted improvement in inhalation technique with DuoResp® Spiromax® compared with other DPIs, resulting in cost savings totalling € 4.79 million over five years. ConClusions: Introducing DuoResp® Spiromax® may reduce the occurrence of unscheduled healthcare events compared with market-leading DPIs, potentially resulting in cost savings. treatment. ConClusions: Inclusion of a novel IBS diagnostic blood panel in the diagnostic pathway has the potential for significant cost savings due to the avoidance of unnecessary testing. objeCtives: UK guidelines for the diagnosis of IBS in patients who meet diagnostic criteria include FBC, ESR, C -reactive protein and testing for coeliac disease to exclude other diseases. Despite these recommendations, referral for procedures such as flexible sigmoidoscopy, colonoscopy and ultrasound scanning continue and in the majority of this patient group, are considered to be unnecessary, subsequently placing an increased cost burden to National Health Services (NHS). A novel IBS diagnostic blood panel has been developed which tests for the presence of two biomarkers associated with IBS-D. This analysis estimates the potential cost impact to the NHS by introducing this test into the diagnostic pathway of IBS. Methods: Budget impact was based on a cost-minimization model to compare the costs associated with two possible diagnostic pathways: (1) with a novel IBS diagnostic blood panel and (2) exclusionary pathway and applied to the UK population 18-65yrs old. Model structure was based on current literature/ guidance from IBS expert. Direct medical expenses include, labs, diagnostic procedures, visits in £ and weighted by utilization provided by a practicing gastroenterologist in the UK. Results: Gastroscopy, flexible sigmoidoscopy, and colonoscopy were the most common diagnostic (instrumental) procedures reported with estimated utilization rates of 55%, 55% and 35%, respectively. Corresponding charges were £200, £400 and £400, respectively. Net savings in the base case of £57 favored the IBS diagnostic blood panel pathway (assumes 75% of test positive patients receive IBS-D treatment) vs the exclusionary pathway. If clinicians use the test 50% of the time for the 30% of the estimated 446,382 people who might have IBS-D who seek treatment, net potential savings to NHS is £12,721,891. ConClusions: Inclusion of a novel IBS diagnostic blood panel in the diagnostic pathway has the potential for significant cost savings due to the avoidance of unnecessary testing. objeCtives: Current guidelines recommend a positive strategy based on symptom criteria without alarm features vs diagnostic exclusion which includes several laboratory and diagnostics procedures to exclude other organic conditions. A novel IBS diagnostic blood panel tests for the presence of two biomarkers associated with IBS-D which can complement the positive strategy. This analysis assesses the cost impact to the Danish healthcare system by introducing this test into the diagnostic pathway. Methods: A budget impact model was based on a cost-minimization decision model developed to compare the costs associated with two possible diagnostic pathways: (1) diagnostic pathway with a novel IBS diagnostic blood panel and (2) exclusionary diagnostic pathway and applied to the Danish population 18-65yrs old. Model structure was based on current literature and guidance from IBS expert clinicians. Direct medical expenses for laboratory tests, diagnostic procedures and visit costs were included in Danish Krone and weighted by utilization rates estimated by a practicing gastroenterologist in Denmark. Indirect cost only included time off work based on a published Danish study. Results: Sigmoidoscopy, colonoscopy and SBFT were the most common diagnostic procedures reported with estimated utilization rates of 35%, 35% and 15%, respectively. Corresponding charges were kr4819, kr4819 and kr1861, respectively. Estimated total base case charges for the IBS diagnostic blood panel pathway ( objeCtives: The diagnosis of diarrhea predominant irritable bowel syndrome (IBS-D) is based on clinical presentation and several laboratory and diagnostic procedures to exclude other organic conditions. A novel IBS diagnostic blood panel has been developed which tests for the presence of two biomarkers associated with IBS-D. This study assesses the cost implications associated with introducing this test into the diagnostic pathway. Methods: A cost-minimization (CM) decision tree model was constructed to compare the costs associated with two possible diagnostic pathways: (1) diagnostic pathway with novel IBS diagnostic blood panel and (2) exclusionary diagnostic pathway (i.e. standard of care). Model structure was based on current literature and guidance from IBS expert clinicians. Costs for
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